Jasti Family Trust Reduces Shareholding in Cohance Lifesciences to 6.36%

Cohance Lifesciences Limited has received a disclosure under SEBI takeover regulations from Jasti Property and Equity Holdings Private Limited, acting as sole trustee of Jasti Family Trust, regarding changes in shareholding patterns. The disclosure, dated February 20, 2026, was submitted to both NSE and BSE pursuant to Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares & Takeover) Regulations, 2011. Shareholding Changes Overview The Jasti Family Trust and its persons acting in concert (PAC) have reduced their combined shareholding in Cohance Lifesciences from 6.59% to 6.36% of the total share capital. The transaction involved 78,76,948 shares, representing 2.06% of the company's total voting capital. Parameter Before Transaction After Transaction Change Total Holdings 2,52,02,957 shares 2,43,26,009 shares -8,76,948 shares Percentage of Total Capital 6.59% 6.36% -0.23% Percentage of Diluted Capital 6.42% 6.20% -0.22% Transaction Details The shareholding reduction was executed through open market transactions and inter-se transfers via block deals on February 18, 2026. According to the disclosure, out of the total 78,76,948 shares involved, 8,76,948 shares (representing 0.23% of total equity) were sold in the open market during the period from September 8, 2025, to January 8, 2026. Entities Involved The disclosure covers the following entities and their respective holdings: Primary Acquirer Jasti Property and Equity Holdings Private Limited (as sole trustee): Reduced from 2,51,92,957 shares (6.59%) to 1,73,16,009 shares (4.53%) Persons Acting in Concert Mrs. Venkata Subbamma Jasti: 6000 shares (negligible percentage) Mr. Venkateswarlu Jasti: 2000 shares (negligible percentage) Mrs. Sudharani Jasti: 2000 shares (negligible percentage) Jasub Property Holdings LLP: Increased from 0 shares to 70,00,000 shares (1.83%) Company Capital Structure Capital Details Number of Shares Equity Share Capital (Before Transaction) 38,25,67,140 Equity Share Capital (After Transaction) 38,25,67,140 Total Diluted Share Capital 39,22,07,995 The company's equity share capital remained unchanged at 38,25,67,140 shares, while the total diluted share capital stands at 39,22,07,995 shares, assuming full conversion of outstanding convertible securities and warrants. Regulatory Compliance The disclosure confirms that the acquirer does not belong to the promoter or promoter group of Cohance Lifesciences Limited. The transaction was conducted in compliance with SEBI regulations, with proper notifications submitted to both stock exchanges where the company's shares are listed - BSE Limited and National Stock Exchange of India Limited. The disclosure was signed by Venkateswarlu Jasti on behalf of Jasti Property and Equity Holdings Private Limited in its capacity as sole trustee of Jasti Family Trust, with copies provided to the company secretary of Cohance Lifesciences Limited. Cohance Lifesciences Limited has released the comprehensive transcript of its quarterly earnings conference call for Q3FY26 and nine months ended December 31, 2025. The detailed transcript provides extensive insights into the company's performance challenges and strategic outlook. Financial Performance Overview The company reported significant revenue challenges during the period, with management acknowledging that recent performance has fallen below expectations. The nine-month FY26 revenue declined by 6.7% to ₹1,650 crore, while Q3 FY26 revenue dropped by 19.5% to ₹545 crore. Financial Metric: Q3 FY26 Nine Months FY26 Change Revenue: ₹545 crore ₹1,650 crore -19.5% (Q3), -6.7% (9M) Gross Margins: Declined 126 bps 72.8% +204 bps (9M) Adjusted EBITDA: ₹85 crore ₹348 crore -43% (9M) EBITDA Margins: 15.5% 21% Margin pressure evident Business Segment Challenges Executive Chairman Vivek Sharma outlined specific factors impacting performance. The Pharma CDMO business experienced a 27% year-on-year decline in Q3, though when adjusted for destocking effects, it showed 7% growth. Destocking in two large commercial products impacted revenue by nearly ₹260 crore as customers normalized inventories. The API Plus segment faced regulatory challenges, with the Nacharam formulation facility receiving a warning letter following OAI status, leading to shipment deferrals of approximately ₹55 crore. The Specialty Chemicals segment reported 32% growth to ₹1.9 billion for nine months. Strategic Developments and Pipeline CEO Pharma CDMO Yann D'Herve highlighted positive developments despite near-term challenges. The company currently supports nine Phase 3 programs across its portfolio, with four molecules expected to move into commercial supply during the coming fiscal year across therapy areas including pulmonary, ADHD, anti-diabetic, and oncology. Pipeline Status: Details Phase 3 Programs: 9 molecules supported Commercial Pipeline: 4 molecules expected in FY27 FDA Approvals: 2 molecules already approved Priority Review: 1 molecule received status Business Development Team: 9 professionals globally Management Outlook The management team revised FY26 revenue outlook to reflect an early-to-mid double-digit decline but expressed confidence in FY27 growth prospects. CFO Himanshu Agarwal emphasized that the challenges are timing and product mix related rather than structural in nature. Despite earning volatility, the business generated free cash flow of ₹175 crore during the first nine months of FY26. The company remains committed to its USD 1 billion sales target, though timing may shift slightly due to current year challenges. Conference Call Availability The earnings conference call was conducted on February 12, 2026, with the complete transcript now available following the company's earlier intimation dated January 22, 2026. The disclosure was made pursuant to Regulation 30 of SEBI regulations, ensuring transparency with stakeholders. Source: We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better. Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians. As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.